-2%
Resiliva (Resmetirom) is indicated, in combination with appropriate dietary modification and regular physical activity, for the treatment of adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) accompanied by moderate to advanced liver fibrosis, corresponding to fibrosis stages F2 to F3.
Resiliva is intended to help reduce liver fat accumulation and improve disease-related liver pathology in eligible patients with NASH.
Use this medicine only as prescribed by a registered physician.
Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist with partial agonistic activity.
THR-β is the predominant thyroid hormone receptor subtype expressed in the liver. Activation of this receptor plays an important role in regulating lipid metabolism and reducing hepatic fat accumulation.
Resmetirom selectively stimulates hepatic THR-β receptors, resulting in:
- Reduction of intrahepatic triglyceride content
- Improvement in liver fat metabolism
- Modulation of genes involved in lipid regulation
- Potential improvement in liver inflammation and fibrosis associated with NASH
In vitro studies have demonstrated that Resmetirom produces substantial THR-β activation while maintaining lower activity at THR-α receptors, contributing to its liver-targeted therapeutic effects.